Navigation Links
Growing Awareness & Increasing Number of Indications Drive the Global Intravenous Immunoglobulin Market, According to a New Report by Global Industry Analysts, Inc.

San Jose, California (PRWEB) July 09, 2013

Follow us on LinkedIn – Immunoglobulins administered through the intravenous route (IVIg) are the most important blood plasma proteins used in the treatment of a variety of labeled and unlabeled indications. The global Intravenous Immunoglobulin (IVIg) market is forecast to witness strong growth supported by increasing acceptance among patients as awareness about the indications for which the protein can be prescribed rises. Increasing population and life expectancy is one of the key factors driving growth of IVIg consumption at the global level and the trend will continue to influence the market positively in the coming years. Approval of new indications and improved diagnosis of conditions are expected to wield a positive effect on the market in the near future. One of the key growth drivers for IVIg is be the protein’s increasing use in immune-mediated neurological disorders and primary immunodeficiencies.

IVIg is also finding increased usage in emerging countries on account of rapid medical technology development, favorable demographics and increasing awareness about treatment with plasma proteins. Expansion of healthcare in developing markets will also be a key growth driving factor for the protein. China, with vast unmet medical needs and a very low per capita consumption, offers robust opportunities for growth. The nation is touted to emerge as one of the leading IVIg consuming markets. Other factors to drive growth in developing countries include improvement in health service provision, increasing funding and expanding range of therapeutic indications for IVIg. On the other hand, key factors with the potential to challenge growth in the medium-to-long term period include healthcare cost containment efforts in industrialized countries; while in emerging countries, the high cost of the therapy has the potential to stifle market expansion.

The potential approval of IVIg products for Alzheimer’s disease in the next few years, and off-label usage of the same over the intervening period is forecast to positively benefit the market. Advances in research have revealed that Intravenous Immunoglobulin (IVIg) fraction from normal human donor blood demonstrates potential to provide passive immunotherapy for Alzheimer’s disease. IVIg could help treat the underlying cause of Alzheimer’s, while also slowing down symptoms of the disease. On the other hand, the positive results of ongoing studies also bring to fore certain issues the industry might possibly face in the event of IVIg showing success in slowing down progress of the Alzheimer’s disease. The question of whether or not the existing plasma manufacturers are capable of adequately meeting the anticipated significant rise in demand will be the most important among such issues.

The market continues to witness structural reformations such as mergers, vertical integrations, and increased manufacturing competencies in a bid for stable growth and market proliferation. The global market for IVIg is currently led by CSL Limited. Other key market participants include Grifols, Baxter and Octapharma. A notable event in the industry during 2010-2011 was the suspension of the marketing activity of Octapharma’s Octagam, one of the leading IVIg products in the industry. The suspension benefited other leading players including Grifols and Baxter, in the form of increase in volume sales of their IVIg products.

As stated by the new market research report on
Intravenous Immunoglobulin (IVIg), the United States represents the largest market, followed by Europe. Asia-Pacific led by China is projected to offer the highest growth opportunity.

Major players in the market include Baxter International Inc., Beijing Tiantan Biological Products Co. Ltd., Bharat Serums and Vaccines Limited, Biotest AG, China Biologic Products Inc., CSL Limited, CSL Behring LLC., Grifols, S.A, Hualan Biological Engineering Inc., Kedrion S.p.A, LFB Group, Octapharma AG, OMRIX Biopharmaceuticals Ltd., Shanghai RAAS Blood Products Co. Ltd., and Sichuan Yuanda Shuyang Pharmaceutical Co. Ltd.

The research report titled "Intravenous Immunoglobulin (IVIg): A Global Strategic Business Report" announced by Global Industry Analysts Inc., provides a comprehensive review of the intravenous immunoglobulin market as well as the plasma products and immunoglobulins markets, current trends, growth drivers, product approvals, product launches, and recent industry activity. The report provides annual revenue estimates and projections in terms of value (US$) by the following geographic markets – The US, Canada, Japan, Europe (France, Germany, Italy, UK, Spain, and Rest of Europe), Asia-Pacific (Australia, China and Rest of Asia-Pacific) and Rest of World.

For more details about this comprehensive market research report, please visit –

About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a leading publisher of off-the-shelf market research. Founded in 1987, the company currently employs over 800 people worldwide. Annually, GIA publishes more than 1300 full-scale research reports and analyzes 40,000+ market and technology trends while monitoring more than 126,000 Companies worldwide. Serving over 9500 clients in 27 countries, GIA is recognized today, as one of the world's largest and reputed market research firms.

Follow us on LinkedIn

Global Industry Analysts, Inc.
Telephone: 408-528-9966
Fax: 408-528-9977
Email: press(at)StrategyR(dot)com
Web Site:

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Newborn Calf Serum Added to Growing Product Suite of Rocky Mountain Biologicals
2. Probiotic Action Comments on the New Use of Probiotics for Oral Health and Shares New Insight What It Means for the Growing US Probiotic Market
3. Apache Atmospheric Tanks Support Growing Biofuel Industry for Sanimax
4. NanoSight, One of the UKs Fastest Growing Biotechnology Companies, Wins a 2013 Queens Award for Enterprise - Innovation
5. Professional Pricing Society Survey Reveals 12 Percent Gain in Manufacturing and Distribution Salaries, Indicating Growing Value of Pricing Expertise
6. Growing Uptake of Genzymes Aubagio at Three Months Post-Launch Is Likely Driven by Perceived Product Convenience Even As Neurologists Search to Identify Appropriate Candidates, According to a Recent BioTrends Report
7. Rapidly Growing Company Extends Global Reach
8. BioInformatics LLC New Market Report – Opportunities for New Players in the Growing Stem Cell Market
9. The 2013 CES: Patents, Legislation Reform, and the Growing Market for Patent Attorneys and Agents Reviewed by Wysebridge
10. Growing Job-Market Niche Inside The Economic Decline: A Wysebridge Review
11. Ramey & Browning Announces New Location and New Hire Firm Is Well Positioned to Address Growing Client Needs In 2013
Post Your Comments:
(Date:11/30/2015)... BETHESDA, Md. , Nov. 30, 2015 /PRNewswire/ ... property development company committed to the fostering and ... on the current and prospective initiatives designed to ... , Chief Executive Officer of Spherix. "Based on ... potential future licensees exceeds $50 billion and Spherix ...
(Date:11/30/2015)... 2015 Human Longevity, Inc. (HLI), the genomics-based, ... Cypher Genomics, Inc., a leading genome informatics company offering ... solutions. The San Diego -based company ... CEO and Co-founder, Ashley Van Zeeland , Ph.D., who ... details of the deal were not disclosed. ...
(Date:11/30/2015)... 30, 2015  Aytu BioScience, Inc. (OTCQB: AYTU), a ... conditions, will present at two upcoming investor conferences. Aytu ... real-time virtual conference, to be held December 3, 2015, ... be held December 2 nd & 3 rd ... and streamed live via webcast. Josh Disbrow ...
(Date:11/30/2015)... 30, 2015  Northwest Biotherapeutics (NASDAQ: NWBO ) ... immune therapies for solid tumor cancers, announced today that ... director, and the Company welcomes Neil Woodford,s ... recent anonymous internet report on NW Bio.  The Company,s ... Linda Powers stated, "We agree with Mr. Woodford ...
Breaking Biology Technology:
(Date:11/17/2015)... , November 17, 2015 Paris ... 2015.   --> Paris from 17 ... DERMALOG, the biometrics innovation leader, has invented the first ... fingerprints on the same scanning surface. Until now two different ... Now one scanner can capture both on the same ...
(Date:11/12/2015)... 12, 2015  A golden retriever that stayed healthy ... (DMD) has provided a new lead for treating this ... Broad Institute of MIT and Harvard and the University ... Cell, pinpoints a protective gene ... disease,s effects. The Boston Children,s lab of Lou ...
(Date:11/10/2015)... 2015 About signature verification ... to identify and verify the identity of an ... the secure and accurate method of authentication and ... individual because each individual,s signature is highly unique. ... dynamic signature of an individual is compared and ...
Breaking Biology News(10 mins):